 |
|
Dose-Related Immunogenicity of Haemophilus influenzae Type b Capsular Polysaccharide—Neisseria meningitidis Outer Membrane Protein Conjugate Vaccine
Victor K. Wong, MD;
Rory Quagliata, MPH, RN;
Robert Adler, MD;
Kwang Sik Kim, MD
Am J Dis Child. 1991;145(7):734-741.
Abstract
| |
• We studied the immunologic responsiveness to Haemophilus influenzae type b capsular polysaccharide—Neisseria meningitidis group b outer membrane protein conjugate vaccine (PRP-NOMP) in children 2 to 42 months of age with vaccine dosages containing 7.5, 15, or 30 µg of PRP. Overall, PRP-NOMP was highly immunogenic. Geometric mean titers of anti-PRP antibody increased from 0.09 to 3.3 mg/L and 6.6 mg/L following each dose of vaccine, respectively, in the 2- to 18-month age group. Similarly, anti-PRP antibody geometric mean titers increased from 0.12 to 5.9 mg/L in the older than 18-month age group. However, we noted an apparent inverse relationship between vaccine dosages and immune responses following two doses of PRP-NOMP in 2- to 18-month-old children. Anti-PRP antibody geometric mean titers were 12.0,6.9, and 3.5 mg/L, respectively, after the second dose of vaccine containing 7.5,15, or 30 µg of PRP. Additional studies are needed to understand the mechanisms responsible for this inverse relationship and also to determine the optimal dosage of PRP-NOMP for young children.
(AJDC. 1991;145:742-745)
Author Affiliations
From the Department of Pediatrics, Childrens Hospital of Los Angeles and the University of Southern California School of Medicine. Dr Wong is now with the Department of Pediatrics, Southern California Permanente Medical Group, Downey.
Footnotes
Accepted for publication January 10, 1991.
Presented in part at the 29th International Conference of Antimicrobial Agents and Chemotherapy, Houston, Tex, September 18, 1989.
Reprint requests to the Division of Infectious Diseases, Childrens Hospital of Los Angeles, 4650 Sunset Blvd, Box 51, Los Angeles, CA 90027 (Dr Kim).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine
Stehr et al.
Pediatrics 1998;101:1-11.
ABSTRACT
| FULL TEXT
Acellular Pertussis Vaccine: Recommendations for Use as the Initial Series in Infants and Children
Committee on Infectious Diseases
Pediatrics 1997;99:282-288.
ABSTRACT
| FULL TEXT
|
